Pre-market trend | JOINN (6127.HK) showed buying signals at a low on April 29, has the rebound window opened?

Today, JOINN's transaction volume was approximately HKD 67 million. Although the absolute volume is not large, the emergence of bullish signals on the daily MACD level has attracted technical attention. The crossover pattern of the DIF line and the DEA line usually indicates that recent selling pressure is waning, and the market has formed a certain degree of balance between buying and selling at the current price level. As a representative enterprise in the domestic preclinical CRO field, JOINN has accumulated a significant decline since its previous high, and the current bullish signal appears at a relatively low level, exhibiting certain characteristics of "oversold recovery." On the news front, the preclinical CRO industry is in a transitional period of capacity digestion and order structure adjustment. The R&D investment of domestic innovative pharmaceutical companies continues to grow, but intensified industry competition has put pressure on unit prices, and JOINN still faces a complex operating environment. On the macro level, the Federal Reserve remains on hold but has not changed its hawkish stance, which may slow the valuation recovery process of the global biopharmaceutical sector. However, the Hong Kong stock market showed a generally warm performance today, with multiple sectors of the Hang Seng Index rising, boosting sentiment for small and mid-cap pharmaceutical stocks. From a technical perspective, JOINN's transaction volume of HKD 67 million is still within a normal range for its daily trading, but it remains insufficient to support a substantial rebound. Bullish signals require sustained volume support to translate into actual price breakthroughs. Recently, attention should be paid to the overall capital flow in the CXO sector and whether there are new orders or performance catalysts at the company level